Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
about
Inhibition of topoisomerase I prevents chromosome breakage at common fragile sitesRelease of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecinOnivyde for the therapy of multiple solid tumorsInorganic nanolayers: structure, preparation, and biomedical applicationsRepair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1.Human Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38Drug interaction prediction using ontology-driven hypothetical assertion framework for pathway generation followed by numerical simulation.Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitorsTransgene-mediated co-suppression of DNA topoisomerase-1 gene in Caenorhabditis elegans.A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group studyABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activationMicrofluidic-integrated laser-controlled microactuators with on-chip microscopy imaging functionalityCyclic peptide-selenium nanoparticles as drug transporters.Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.Anticancer Alkaloids from Trees: Development into Drugs.Wide field-of-view on-chip Talbot fluorescence microscopy for longitudinal cell culture monitoring from within the incubatorAssociation between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Radiosensitizers in cervical cancer. Cisplatin and beyond.Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization.DNA topoisomerases participate in fragility of the oncogene RET.In-vitro Cellular Uptake and Transport Study of 9-Nitrocamptothecin PLGA Nanoparticles Across Caco-2 Cell Monolayer ModelNanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.Assessment of anti-cytogenotoxic effects of quercetin in animals treated with topotecan.Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenograftsArsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).Repair of topoisomerase I-mediated DNA damage.A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model.Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expressionSurface decorated gold nanoparticles by linear and cyclic peptides as molecular transporters.Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.Pharmacogenetic pathway analysis of irinotecan.UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.
P2860
Q24622097-D233F499-D476-4AEF-AA5B-CB12498B0D96Q24795283-83E74760-6358-42BD-9235-9E82B0A33405Q26747166-0E7B67C2-ED1C-49F0-BB7A-CCA63A6E96FCQ26781178-67D47589-CB61-4AC9-8A90-54FCEB351EEFQ27934003-67249B61-9C6C-4B60-B2F7-E09232A54ED9Q28550622-EE99E9A0-E65C-4045-9846-BDCBEC3E8FF6Q30482258-B8E29F14-DCB7-44D2-89A9-D8F562BC8F45Q33380081-A0C8D84E-066E-4A31-8364-3C4EB7A1DAB1Q33533630-FE69420D-58C3-4FCB-B1E5-E413E74419CCQ33725863-EE32F355-45D7-47FB-962B-E33EE992BB76Q33760468-9D61E568-B6E4-44D2-8586-EE114394FF34Q33807755-90315B27-0DE0-485C-B2F4-42783F0C0251Q33892921-3ABBEB15-0FCC-4F5C-A841-88B634F31126Q34128473-54F9D2FF-E9BC-48B9-8E7F-FB4E8A97AD54Q34293631-4BA201BC-AF6B-4B8B-8ACF-5422A24A329EQ34455658-F908870C-DFFB-4FFF-87FE-A08A6CE25B30Q34549113-9F97AE7C-D69C-4D08-9F21-AD88DA462C65Q34563742-D142B4FC-A4A4-43AB-9ED3-74CB31E4D7F3Q34629650-E30FB179-4D91-42C9-811D-3BA3BA8CD617Q34684307-6369AFFE-0379-420A-88DA-B27BB8DF35F2Q34887304-70454124-3E72-47E3-85A4-F1DEBD1AA755Q34990644-84A89B1B-F575-44D3-9BF3-7862EBAE971BQ35046472-5D776227-7ED2-47B6-9D79-945A407A5266Q35182759-EB5FBB78-DC56-4D91-AB23-0BBF037F4468Q35185625-F1CFF13C-E6EA-4E14-9B99-48FA40F0B4C3Q36185395-8D0630AF-2DB6-4E76-A5FC-2E17125888D3Q36253212-A1C0C7DA-5ECC-4A41-A5D6-3EF66D311147Q36356001-05B27C91-BD04-467F-978F-73C4BB173946Q36557533-C0D51FAC-E5C4-4DB6-A637-01D36D6A18F1Q36615012-AE5CCA88-E26B-4E7B-A2AE-8D830D4CE33DQ36642304-8CDEBC94-7EAA-4083-B19B-87B273EB6BC8Q36921799-37A5DCAE-A30B-4BCC-A7F6-0A81C8533DD4Q37262485-76C86EAC-168E-4168-A9A9-6E3BC828D6BBQ37355096-3877E8CC-FA98-4C61-A3BC-90E3017CDF3CQ37381224-306BD2B1-2B56-415E-AE9F-4ED2BFE328B8Q37402459-7C81EBE2-3AA2-4467-9280-03C2EA6AF259Q37441604-6531B954-AE5B-4955-A7CC-42AAB1A1F02AQ37695391-E2421DE0-5FC4-488A-ACC7-7041B69FA0F7Q37698616-A223AB8C-1947-458D-A6A9-9CD5DC4F4321Q37887337-303B8EA2-4191-45A6-A248-B362A9661F46
P2860
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Current perspectives on the cl ...... elopment of the camptothecins.
@ast
Current perspectives on the cl ...... elopment of the camptothecins.
@en
Current perspectives on the cl ...... elopment of the camptothecins.
@nl
type
label
Current perspectives on the cl ...... elopment of the camptothecins.
@ast
Current perspectives on the cl ...... elopment of the camptothecins.
@en
Current perspectives on the cl ...... elopment of the camptothecins.
@nl
prefLabel
Current perspectives on the cl ...... elopment of the camptothecins.
@ast
Current perspectives on the cl ...... elopment of the camptothecins.
@en
Current perspectives on the cl ...... elopment of the camptothecins.
@nl
P1476
Current perspectives on the cl ...... velopment of the camptothecins
@en
P2093
Jeffrey G Supko
P304
P407
P577
2002-03-01T00:00:00Z